XNASVRDN
Market cap1.52bUSD
Jan 08, Last price
19.15USD
1D
-8.42%
1Q
-12.95%
Jan 2017
282.24%
IPO
126.63%
Name
Viridian Therapeutics Inc
Chart & Performance
P/E
—
P/S
4,830.97
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
86.69%
Rev. gr., 5y
-48.16%
Revenues
314k
-82.28%
Net income
-238m
L+89.51%
CFO
-184m
L+96.26%
Earnings
Feb 25, 2025
Profile
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
IPO date
Jun 18, 2014
Employees
86
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 314 -82.28% | 1,772 -40.20% | |||||||
Cost of revenue | 256,086 | 136,831 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (255,772) | (135,059) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,430) | ||||||||
Tax Rate | |||||||||
NOPAT | (255,772) | (130,629) | |||||||
Net income | (237,734) 89.51% | (125,444) 57.96% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 125,069 | 292,057 | |||||||
BB yield | -12.83% | -31.16% | |||||||
| Debt | |||||||||
Debt current | 843 | 613 | |||||||
Long-term debt | 21,048 | 5,258 | |||||||
Deferred revenue | 573 | 861 | |||||||
Other long-term liabilities | 989 | 1,172 | |||||||
Net debt | (455,479) | (418,679) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (184,170) | (93,838) | |||||||
CAPEX | (898) | (797) | |||||||
Cash from investing activities | (94,252) | (115,126) | |||||||
Cash from financing activities | 225,670 | 322,244 | |||||||
FCF | (256,178) | (131,510) | |||||||
| Balance | |||||||||
Cash | 477,370 | 424,550 | |||||||
Long term investments | |||||||||
Excess cash | 477,354 | 424,461 | |||||||
Stockholders' equity | (518,514) | (346,003) | |||||||
Invested Capital | 983,146 | 748,358 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 44,755 | 32,087 | |||||||
Price | 21.78 -25.44% | 29.21 47.75% | |||||||
Market cap | 974,774 4.00% | 937,270 297.77% | |||||||
EV | 725,811 | 660,738 | |||||||
EBITDA | (255,250) | (134,804) | |||||||
EV/EBITDA | |||||||||
Interest | 1,847 | 486 | |||||||
Interest/NOPBT | |||||||||